Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?

TheFly reported connected June 16 that Canaccord expert Whitney Ijem accrued the terms people connected RYTM to $151 from $143 portion maintaining a Buy rating. The update followed a affirmative interim reappraisal from the Phase 2 survey of setmelanotide successful Prader-Willi syndrome (PWS). Canaccord highlighted continued BMI improvements with longer attraction exposure, with reductions reaching 3.06% astatine six months compared with 1.84% astatine 3 months. The steadfast besides noted that 8 of 10 patients with mean to terrible baseline hyperphagia achieved a clinically meaningful simplification of astatine slightest 7 points connected the HQ-CT assessment.

On June 15, Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced caller information presentations from ENDO 2026 highlighting results from its MC4R agonist programs successful acquired hypothalamic obesity, Bardet-Biedl syndrome, and Prader-Willi syndrome. The institution reported affirmative findings showing improvements successful weight-related outcomes and hyperphagia crossed aggregate diligent populations. Data included semipermanent setmelanotide results successful acquired hypothalamic obesity, real-world outcomes successful BBS patients, and Phase 2 results successful PWS. The findings supported the imaginable of MC4R pathway therapies to code uncommon neuroendocrine disorders with constricted attraction options and demonstrated continued advancement crossed RYTM's improvement programs.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is simply a commercial-stage biopharmaceutical institution processing precision medicines for uncommon familial obesity and neuroendocrine disorders.

While we admit the imaginable of RYTM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.